Analysts’ Perspective: Virtusa (VRTU), Supernus Pharmaceuticals (SUPN), Intra-Cellular Therapies (ITCI)

Virtusa Corp. (NASDAQ:VRTU) shares were upgraded by analysts at Maxim Group from Hold to Buy rating with a price target of $51.

Virtusa Corp. engages in the provision of information technology consulting, technology implementation, and application outsourcing services.

*

Brokerage Firm Stifel upgraded Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) shares from Hold to Buy rating with a price target of $47.

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases.

*

Investment Analysts at SunTrust upgraded Intra-Cellular Therapies Inc. (NASDAQ:ITCI) shares from Hold to Buy rating.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/